Journal of Cell Science & Therapy
Open Access
ISSN: 2157-7013
+44 1300 500008
ISSN: 2157-7013
+44 1300 500008
Mrinmay Kumar Mallik
Accepted Abstracts: J Cell Sci Ther
Tumor recurrence is considered to be one of the biggest culprits, behind the poor prognosis of glioblastomas. Using published facts on primary glioblastomas, with special reference to cancer stem cells and their recently described heterogeneity, a hypothesis is being proposed which speculates the possible role of therapy mediated neoplastic cell loss in promoting the process of relapse in these tumors. Th e mechanisms by which such a phenomenon could be functional, has been integrated into a double version theoretical model, which envisages glioblastomas as neoplasms comprising of multiple, diff erentially regulated and dynamically distinct neoplastic compartments (named as active and back up compartments in this article) supported by their own complement of cancer stem cells, wherein therapy mediated cell loss, which mainly aff ects the size of the active compartment, results in abrogating the inhibitory eff ect of the active compartment on the back up compartment, thereby leading to the activation of the back up compartment. Th is activation contributes towards tumor recurrence. Th e possibility of the existence of such a phenomenon could have strong implications on management and prognosis of these tumors. Th is work aims to provoke discussion and generate new ideas for further research
Dr Mrinmay Kumar Mallik obtained his MD in Pathology from PGIMER Chandigarh India in 1996. Although he works as a clinical cytopathologist at the Cytopathology laboratory his main area of interest since 2005 has been the theoretical aspects regarding cancer stem cells specially cancer stem cells in gliomas. After carefully analyzing a large volume of literature concerning cancer stem cells in gliomas he put forward a novel theoretical model which attempts to explain recurrence in glioblastomas. This was published in the Journal of Theoretical Biology in October 2010